Description

NIFTY® is a world-leading non-invasive prenatal test(NIPT) product independently developed by BGI Genomics and already tested on 15+ million patients. By collecting >5 mL of maternal peripheral blood, extracting cell-free DNA, and using low-depth whole-genome sequencing technology, combined with bioinformatics analysis, the risk of fetal chromosomal abnormalities can be determined.

It is a safe and accurate method for detecting T21, T18 and T13, and can expand detection for other autosomal aneuploidies, sex chromosome aneuploidies, and pathogenic chromosomal deletions/duplications (CNVs).

Parameters Included:

Common Autosomal Trisomies

• Trisomy 21 (Down syndrome)
• Trisomy 18 (Edwards syndrome)
• Trisomy 13 (Patau syndrome)

Rare Autosomal Trisomies

• Trisomy 9
• Trisomy 16
• Trisomy 22

Sex Chromosome Aneuploidies

• XO (Turner syndrome)
• XXY (Klinefelter syndrome)
• XXX (Triple-X syndrome)
• XYY (Jacobs syndrome)

9/21/10 micro deletion/duplication, including:

• DiGeorge syndrome (22q11.2 deletion)
• 1p36 deletion syndrome
• Prader-Willi/ Angelman syndrome
• Smith-Magenis syndrome
• Cri-du-Chat syndrome
• 4p16.3 deletion syndrome
• Distal 18q deletion syndrome
• 18p deletion syndrome
• 9p deletion syndrome
• Jacobsen Syndrome

Incidental findings

• Other autosomal aneuploidies
• & ≥5Mb CNVs

Sex Indication

• Y chromosome detection

Advantages

• Accurate: Over 99% sensitivity for trisomy 21, 18, and 13.
• Safe: Only maternal peripheral blood is needed, no risk to mother or fetus.
• Trusted: Over 15,000,000 samples processed worldwide.
• Comprehensive: NIFTY® Pro detects over 100 genetic conditions.
• Early: Screen as early as the 10th week of pregnancy.

Suitability of the test 

• Applicable for: Any age of pregnant women from 10 weeks gestation.
• Suitable for pregnancies: Singleton, twins, and vanishing twin syndrome (VTS) pregnancies.
• IVF pregnancies: Suitable for pregnancies achieved through in vitro fertilization.